Atorvastatin or Ezetimibe: What Is the Difference

Atorvastatin and ezetimibe lower the level of “bad” cholesterol, but they do so in fundamentally different ways: the first inhibits its synthesis in the liver, the second — its absorption in the intestine. This is exactly why they complement each other excellently, but are not an equivalent replacement. The editorial team breaks down how these drugs differ in mechanism, strength of action and evidence base.

Two sources of cholesterol in the body

Cholesterol in the blood has two main sources. The body synthesizes the larger part itself, primarily in the liver. It obtains the smaller part from the intestine — from food and from bile, which the liver secretes into the intestine and which is partly reabsorbed.

These two pathways are linked by a compensation mechanism. If you block synthesis, the body tries to absorb more cholesterol from the intestine. If you block absorption, the liver increases synthesis. This interplay explains why combining two drugs gives a greater effect than increasing the dose of one of them.

Atorvastatin acts on the first pathway — synthesis. Ezetimibe — on the second, absorption. The final result of both is the same: the liver receives less cholesterol, increases the number of LDL receptors and more actively “pulls” low-density lipoproteins out of the blood.

Lowering LDL is the main goal of lipid-lowering therapy, since it is precisely these particles that penetrate the vessel wall and form atherosclerotic plaques. The ESC/EAS 2019 guidelines regard LDL as a causal factor of atherosclerosis.

Atorvastatin: mechanism and properties

Atorvastatin is an inhibitor of HMG-CoA reductase, the key enzyme of cholesterol synthesis. It is one of the most studied and most widely used statins in the world. The drug is lipophilic, metabolized predominantly by the enzyme CYP3A4 with the formation of active metabolites that prolong its action.

The dose range per labeling is from 10 to 80 mg per day. Doses of 10–20 mg are classified as moderate-intensity therapy, 40–80 mg — as high intensity, which lowers LDL on average by 50% and more. Doubling the statin dose adds only a few percent of effect — the so-called “rule of six percent.”

Besides lowering LDL, statins have pleiotropic effects: they moderately lower triglycerides, reduce inflammation in the vessel wall and stabilize plaques. Part of the benefit of statins in studies may be related precisely to these properties.

Since atorvastatin depends on CYP3A4, its concentration is increased by clarithromycin, some antifungal and antiretroviral drugs, and also large amounts of grapefruit juice. This increases the risk of muscle complications.

Ezetimibe: mechanism and properties

Ezetimibe blocks the protein NPC1L1 (Niemann-Pick C1-Like 1) on the surface of the cells of the small intestine. This protein is responsible for transporting cholesterol from the lumen of the intestine into the cells. Without it, a significant part of dietary and biliary cholesterol is excreted in the feces.

The standard dose per labeling is 10 mg per day, and, unlike statins, it is not titrated. Ezetimibe is metabolized by glucuronidation, does not depend on CYP3A4 and participates in enterohepatic circulation, which ensures a long action.

As monotherapy, ezetimibe lowers LDL relatively modestly — by approximately 15–20%. However, when added to a statin it provides an additional reduction that usually exceeds the effect of doubling the statin dose.

Ezetimibe has no pronounced effect on triglycerides or inflammation, and its advantage is very good tolerability and a minimal number of drug interactions.

Strength of action and evidence base

The benefit of atorvastatin has been proven in numerous studies. In ASCOT-LLA (Sever et al., 2003), atorvastatin 10 mg in patients with hypertension and average or below-average cholesterol levels reduced the rate of coronary events so much that the study was stopped early. In TNT (LaRosa et al., 2005), in patients with stable ischemic disease, a dose of 80 mg outperformed 10 mg in reducing major cardiovascular events.

For ezetimibe, the key study is IMPROVE-IT (Cannon et al., 2015). Patients after acute coronary syndrome had ezetimibe or placebo added to simvastatin. The combination gave a lower LDL and a modest but statistically significant reduction in cardiovascular events. This result confirmed: lowering LDL is beneficial regardless of the mechanism.

An important nuance: there are no independent large studies of ezetimibe as monotherapy with hard endpoints. Its benefit for the heart has been shown precisely in combination with a statin.

Side effects and interactions

The safety profile of the two drugs differs noticeably.

• Atorvastatin:muscle symptoms (pain, weakness), an increase in liver enzymes, a small increase in the risk of diabetes in predisposed people; rarely — myopathy and rhabdomyolysis, more often at high doses and with interactions via CYP3A4.
• Ezetimibe:tolerated close to placebo; possible abdominal discomfort, diarrhea, headache; in combination with a statin — somewhat more frequent increase in liver enzymes.

Both drugs are contraindicated in pregnancy and active liver diseases. Ezetimibe is not recommended in moderate and severe hepatic insufficiency.

In physically active people, muscle symptoms on a statin require careful assessment: some of them are related to training, not to the drug. The EAS consensus (Stroes et al., 2015) describes a sequential algorithm for assessing such complaints.

Editorial conclusions

Atorvastatin inhibits cholesterol synthesis and is the foundation of lipid-lowering therapy with a powerful evidence base. Ezetimibe blocks cholesterol absorption and works best as an addition to a statin.

In terms of strength of action, atorvastatin significantly outperforms ezetimibe in monotherapy, but the combination of the two drugs gives more than doubling the statin dose.

Ezetimibe stands out for good tolerability and a minimum of interactions, which makes it an important option for people with intolerance to high doses of statins.

Practical selection scenarios are examined in the article “Atorvastatin vs Ezetimibe: What to Choose and for Whom.” We also recommend “Rosuvastatin or Citrus Bergamot: What Is the Difference” and material on the lipid profile for athletes.

References

1. Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372(25):2387–2397.
2. LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352(14):1425–1435.
3. Sever PS, Dahlöf B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial–Lipid Lowering Arm (ASCOT-LLA). Lancet. 2003;361(9364):1149–1158.
4. Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111–188.
5. Cholesterol Treatment Trialists' (CTT) Collaboration; Baigent C, Blackwell L, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670–1681.
6. Stroes ES, Thompson PD, Corsini A, et al. Statin-associated muscle symptoms: impact on statin therapy — European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. Eur Heart J. 2015;36(17):1012–1022.